Table 3.

Impact of prior treatment on response to cell transfer therapy using selected TILs

n (%)aORb
TotalCRPR
All patients9320 (22)32 (34)52 (56)
Prior treatment
 None5 (5)2 (40)1 (20)3 (60)
 IL-277 (83)14 (18)28 (36)42 (54)
 Chemotherapy40 (43)7 (18)16 (40)23 (58)
 IFN52 (56)11 (21)17 (33)28 (54)
 Anti-CTLA411 (12)5 (45)2 (18)7 (64)
 IL-2+ chemotherapy37 (40)6 (16)16 (43)22 (59)
 IL-2+ anti-CTLA48 (9)3 (38)1 (13)4 (50)
 IL-2+ anti-CTLA4+ chemotherapy6 (7)2 (33)1 (17)3 (50)
  • aThe percentage of patients with a CR, PR, or OR in each group who had received the prior treatment.

  • bNo group is statistically different from any other.